The KEYNOTE-012, a phase Ib trial was the first time that pembrolizumab, an anti-PD-1 mAb, was used as an immunotherapeutic approach for patients with advanced GC and PD-Ligand 1 (PD-L1) positive (Table 2) [30]. Here, PDCD1 is linked to gastric cancer.